Viridian Therapeutics (NASDAQ:VRDN) Trading Down 2.7%

Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Free Report)’s share price fell 2.7% on Wednesday . The stock traded as low as $12.97 and last traded at $13.10. 416,067 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 926,507 shares. The stock had previously closed at $13.46.

Analysts Set New Price Targets

Several research firms have recently weighed in on VRDN. Wolfe Research began coverage on shares of Viridian Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $29.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a report on Tuesday. LADENBURG THALM/SH SH cut shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. HC Wainwright decreased their price target on shares of Viridian Therapeutics from $37.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, B. Riley cut shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $25.00 to $20.00 in a report on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Read Our Latest Stock Report on Viridian Therapeutics

Viridian Therapeutics Trading Down 5.4 %

The firm’s 50-day simple moving average is $13.84 and its 200-day simple moving average is $17.39. The company has a quick ratio of 23.99, a current ratio of 23.99 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $793.95 million, a PE ratio of -2.77 and a beta of 1.03.

Viridian Therapeutics (NASDAQ:VRDNGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.28. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the business posted ($1.61) earnings per share. The company’s revenue was down 26.5% on a year-over-year basis. Equities analysts expect that Viridian Therapeutics, Inc. will post -3.61 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. raised its stake in shares of Viridian Therapeutics by 19.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after acquiring an additional 799 shares during the last quarter. Swiss National Bank raised its stake in shares of Viridian Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 67,200 shares of the company’s stock valued at $1,464,000 after acquiring an additional 800 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Viridian Therapeutics by 9.7% during the first quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock valued at $209,000 after acquiring an additional 1,058 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Viridian Therapeutics by 4.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock valued at $505,000 after acquiring an additional 1,135 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Viridian Therapeutics by 9.7% during the fourth quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock valued at $378,000 after acquiring an additional 1,545 shares during the last quarter.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

Read More

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.